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Coronavirus disease 
2019 (COVID-19) has be-
come a global pandemic 
and an unexpected public 
health crisis [1]. Although 
respiratory symptoms 
are common clinical man-
ifestations of COVID-19, 
some patients will experience cardiovascular (CV) 
complications [1, 2]. Many previous studies have 
been reported that pre-existing CV diseases (CVD) 
and in-hospital myocardial injury are both key de-
terminants of COVID-19 mortality [2]. Moreover, 
COVID-19 related cardiac injury occurs more fre-
quently in patents with pre-existing CV comorbidi-
ties [3]. However, whether the increased mortality 
in patients with cardiac injury can be attributed to 
a higher prevalence of comorbidities in COVID-19 
patients remains unclear.
In this issue of “Cardiology Journal”, Lorente-
-Ros et al. [4] described the associations between 
cardiac injury and mortality in COVID-19 patients, 
and whether this link was related to patient co-
morbidities. Between March 18 and March 23 in 
2020, 707 consecutive adult patients admitted to 
a large tertiary hospital with confirmed COVID-19 
were retrospectively included. The demographic 
data, medical history, laboratory results and clini-
cal outcomes were gathered, and the Charlson 
comorbidity index (CCI) was calculated to quantify 
the degree of comorbidities. COVID-19 associated 
cardiac injury is defined if the level of serum car-
diac troponin (cTn) I/T 
increase is above the 99th 
percentile upper refer-
ence limit after exclud-
ing obstructive coronary 
artery disease [2, 5]. 
The results showed that 
20.9% of COVID-19 pa-
tients presented with 
cardiac injury [4]. This 
finding is similar with 
previous findings in Wuhan, China [6–8]. In the 
multivariate-adjusted Cox proportional hazard 
regression model, cTnI, age, C-reactive protein 
and creatinine on admission were independently 
associated with a higher risk of all-cause mortality 
within 30 days [4]. In a second Cox model, adjusted 
for CCI to account for age and comorbidity, cTnI 
was also proved as the independent indicator 
associated with higher risk of mortality (hazard 
ratio 2.31, 95% confidence interval 1.57–3.39, 
p < 0.001) in COVID-19 [4]. Thus, cardiac injury is 
independently associated with mortality irrespec-
tive of baseline comorbidities. And the addition 
of cTnI to multivariate regression models signifi-
cantly improves their performance in predicting 
mortality in a time-dependent receiver operating 
characteristic curve [4].
In another study, Cao et al. [9] included 244 
COVID-19 patients with no pre-existing CVD, and 
revealed that 11% of these patients had increased 
cTnI levels (> 40 ng/L) on admission. And serum 
cTnI levels provided independent prediction to 
both disease severity and 30-day in-hospital mor-
tality in these COVID-19 patients with no prior 
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CVD [9]. It further indicated that myocardial injury 
is an independent predictor for mortality irrespec-
tive of CV comorbidities in COVID-19.
Based on the predictive value of troponin to 
mortality, the determination of cardiac injury bio-
markers on admission and its combination with CCI 
can classify patients into three risk groups (high, 
intermediate and low), which may shed important 
light on the clinical management of COVID-19. The 
elevation of troponin may be interpreted as an early 
warning sign with aggravating the disease, identify-
ing those patients who might require careful moni-
toring. Not only that, aggressive cardioprotective 
treatments could be applied to COVID-19 patients 
with cardiac injury in a timely manner.
Circulating cardiac troponin is a marker of car-
diac injury, including but not limited to myocarditis 
or myocardial infarction. Potential mechanisms 
of myocardial injury in COVID-19 include viral 
myocarditis induced by virus infection and autoim-
mune response, coronary microvascular ischemia 
mediated by endothelia cell dysfunction, stress car-
diomyopathy and tachyarrhythmia attributable to 
adrenergic stimulation, atherothrombosis triggered 
by the proinflammatory and prothrombotic state, 
and myocardial oxygen supply or demand imbalance 
with hypoxia, hypotension, or tachycardia [10]. 
Thus, myocardial injury can occur independently 
or on the basis of comorbidity in COVID-19.
Treatments for myocardial injury in COVID-19 
mainly refer to anti-viral therapy and anti-inflam-
matory therapy. Since the outbreak of COVID-19, 
a few anti-virus agents have been proposed. Among 
them, the most hopeful one is remdesivir. In the 
randomized controlled trial (RCT) of COVID-19, 
remdesivir did not show obvious clinical benefit for 
severe COVID-19 patients [11]. Although no anti-
viral drugs have been proved to be effective by RCT, 
several drugs may have certain therapeutic effects 
after clinical observation. In the Chinese man-
agement guidelines for COVID-19, interferon-a, 
ribavirin, chloroquine phosphate and abidol could 
be recommended [12]. For anti-inflammatory 
drugs, corticosteroid could be the first one shown 
to reduce the mortality of COVID-19 patients [2]. 
Also in the Chinese management guideline for 
COVID-19, patients with progressive hypoxia, 
rapid progress in lung imaging, and excessive 
inflammatory response are advised to use glu-
cocorticoid within a short time [12]. The other 
anti-inflammatory or immunomodulation therapies 
such as intravenous immunoglobulin, anti-interleu-
kin-6 receptor monoclonal antibody, convalescent 
plasma, blood purification, mesenchymal stem cell 
infusion, among others have also proved to be ef-
fective in a portion of COVID-19 patients [12]. For 
severe and critical COVID-19 patients with cardiac 
injury, it is necessary to carry out respiratory and 
circulatory support treatment such as mechanical 
ventilation, continuous renal replacement therapy, 
and extracorporeal membrane oxygenation.
COVID-19 patients with pre-existing medical 
conditions are susceptible to cardiac injury. How-
ever, myocardial injury is an independent predic-
tor for mortality, irrespective of comorbidity in 
COVID-19. The management of myocardial injury 
in COVID-19 is of great importance and should be 
continuously improved in future research.
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